Medindia59m
Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathway
Financing Led by RA Capital Management with Participation from Other Existing Investors Canaan Partners and Cenova Capital VT3989 is the Only TEAD Autopalmitoylation Inhibitor ...